- St Jude's influenza patents, with US government rights
- CDC FOIA regarding intellectual property on avian flu intellectual property rights
- KEI Special 301 supplemental comments: Compulsory Licensing not restricted to "Emergencies" or "Measure of Last Resort"
- KEI's supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs
- KEI's Feb 27, 2015 Supplemental Comments to USTR Regarding Research and Development
- WTO TRIPS Council (February 2015): EU mounts defense of tobacco plain packing measures in the Republic of Ireland and the UK
- A few reactions to the USTR Special 301 Hearing
- KEI comments at February 24, 2015 USTR Special 301 Hearing
- WTO TRIPS Council (February 2015): Bangladesh statement (on behalf of LDC Group)- Extension of the 2016 transitional period
- WTO TRIPS Council (February 2015): LDC Group statement on Non-Violation and Situation Complaints
The December 9, 2014 SCCR morning session started with the Chair's summary of yesterday informals. The delegates discussed 3 charts. The first chart called "a technological platforms chart" is supposed to clarify the scope of protection of the new instrument, the broadcasters' treaty. The second chart is called "a rights chart". And additionally, the Chair prepared a third chart which was called a definitions chart, which contained the definitions of broadcasting organization, broadcasting transmission and signal.
The morning session of SCCR 29 (Dec 8-12, 2014) ended with a coffee break which will be followed by informals (that we are not allowed to report on at this point). After the usual decisions this morning i.e, Adoption of the agenda of the twenty ninth session then Accreditation of new non governmental organizations (and yes, the Program on Information Justice and Intellectual Property (PIJIP) is in!) we had the Adoption of the Report of the Twenty-Eighth Session of the Standing Committee on Copyright and Related Rights.
The World Intellectual Property Organization's 29th Standing Committee on Copyright and Related Rights (SCCR) is meeting in Geneva from 8-12 December 2014. WIPO has a live stream of the proceedings; the password is sccr29. The opening statement of the European Union is contained below.
The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/"search term"), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/"united states of america"), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.
On Wednesday, 10 December 2014, Knowledge Ecology International (KEI) will convene a side event entitled, "The Broadcasting Treaty: A Solution in Search of a Problem?"; the event will take place in Room B of the World Intellectual Property Organization (WIPO) from 13:30 to 15:00.
The NIH has a notice about a proposed rule that "clarifies and expands requirements for the submission of clinical trial registration and results information to the ClinicalTrials.gov database." Comments are due on or before February 19, 2015. We may ask the NIH to consider expanding the trials registry to include more information on the economics of clinical trials.
Here is a link to the Regulations.Gov docket for the proposed rule:
On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs.
Leading up to the release of Professor Joe DiMasi's latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.
We received 26 guesses, ranging from $1.157 billion to $5 billion.
Joel Lexchin's estimate ($2.47 billion) was the closest to DiMasi's number ($2.558 billion). It was also the 5th largest estimate.
A complete list of submissions is below.
Name & Guess
Charles Clift - 1.157 billion
Nicole H - 1.2 billion
Ronald Rader - 1.55 billion
Wouter Deelder - 1.655 billion
The Tuft Center for Study of Drug Development (CSDD) has just concluded a press conference, and issued a press release about their new study of drug development costs. The key number is $2.558 billion.
When the new Tufts study on the costs of R&D for development of a new drug is released Tuesday at 10AM, here are 10 things to look for:
We will be sharing some data on 2005 to 2014 oncology approvals, including the size of the trials cited in the medical review, and the orphan status.
The spreadsheet we are working on updating is published here:
KEI Research Note: Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary resultsSubmitted by James Love on 17. November 2014 - 11:50
A copy of the research note is also available here as a pdf file: http://keionline.org/sites/default/files/kei-rn-2014-3.pdf
KEI Research Note 2014:3
Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
November 17, 2014
On 14 March 2014, KEI published "Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules" in which we provided an analysis of the Global Fund's plans to create a global framework for tiered pricing enforced by the rules of the World Trade Organization (WTO).
WIPO patent committee engaged in heated talks on work sharing, limitations & exceptions, client confidentialitySubmitted by thiru on 6. November 2014 - 11:38
6 November 2014